Ocuphire Pharma, Inc.

Restoring Vision and Clarity

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.

SEE WHO WE ARE

CORPORATE PRESENTATION

A Clear-sighted Product Pipeline

Nyxol®

Targets: Pharmacologically-induced Mydriasis, Presbyopia, and Dim Light or Night Vision Disturbances

Nyxol® Eye Drops is a once-daily preservative-free eye drop formulation designed to reduce pupil size and improve visual acuity.

View Nyxol

APX3330

Targets: Diabetic Retinopathy and Diabetic Macular Edema

APX3330 is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammatory pathways relevant to retinal and choroidal vascular diseases.

View APX3330

Our Clinical Trials

Ocuphire Pharma plans to readout 4 clinical trials with a potential NDA filing for the RM indication in 2022.

View Clinical Trials

Latest News

Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update

Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August

View Release

Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance

View Release

Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July

View Release

Stock Snapshot

View Investor Relations